Silibinin: an old drug for hematological disorders.
In this report, we review the up-to-date findings of more potency roles of silibinin in β-thalassemia (β-TM), acute myeloid leukemia (AML), anaplastic large cell lymphoma (ALCL) and multiple myelomas (MM) therapy and attempt to clarify the mechanisms underlying its effects. There are two viewpoints: First, The functional mechanisms of silibinin in AML cells via regulating cell differentiation to exert anti-cancer effect; Second, combination treatment strategy may be a good choice.
PMID: 29179521 [PubMed]
Source: Oncotarget - Category: Cancer & Oncology Tags: Oncotarget Source Type: research
More News: Acute Leukemia | Acute Myeloid Leukemia | Alcoholism | Bladder Cancer | Breast Carcinoma | Cancer | Cancer & Oncology | Carcinoma | Chronic Leukemia | Colon Cancer | Colorectal Cancer | Flavonoids | Gallbladder Cancer | Hematology | Hepatitis | Hepatocellular Carcinoma | Leukemia | Liver | Liver Cancer | Lymphoma | Study | Toxicology | Urology & Nephrology